You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):復創醫藥研發之BTK抑制劑完成首例受試者給藥
阿思達克 04-21 10:29
復星醫藥(02196.HK)公布,旗下復創醫藥自主研發的選擇性BTK抑制劑FCN-647片的I期臨床研究,於4月20日完成首例受試者給藥。

該研究主要評估FCN-647在復發或難治性B細胞惡性腫瘤患者中的安全性、耐受性、藥代動力學特徵和初步抗腫瘤活性。

公司表示,復創醫藥聚焦臨床急需的抗腫瘤及代謝類疾病的創新藥研究,目前9個項目已成功進入臨床研究,其中1個項目已進入三期臨床試驗階段,3個項目已進入二期臨床試驗階段,5個項目已進入一期臨床試驗階段,另有6-7個項目正在進行臨床前研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account